iNADO Quarterly Report 1&2/2016 / Institute of National Anti-Doping Organisations (iNADO). - Bonn : iNADO, 2016

(See attached pdf-file for more information)

This communication goes to iNADO’s 59 Members. It is the first quarterly corporate report to share information on iNADO’s activities (this one covering the first two quarters of 2016).
iNADO is happy to answer any questions on your Institute’s activities.

Please send your questions to info@inado.org

Contents:

- New Members
- New iNADO Partnerships
- iNADO Attendance at Anti-Doping Conferences/Meeting
- NADOs Visited
- iNADO Webinars
- iNADO Board Meetings
- iNADO Public Statements
- iNADO Updates
- iNADO Member Communications
- iNADO Board Meetings
- Added documents on iNADO Website
- Other iNADO Projects and Activities

Copyright © 2016, iNADO, All rights reserved.

Notice - Meldonium / World Anti-Doping Agency (WADA). - 2016

An updated guidance regarding the results management and adjudication process to be followed for cases involving meldonium.

- Urine Collection Date: from 1 January to 29 February 2016
- Urine Collection Date: from 1 March to 30 September 2016
- Urine Collection Date: after 30 September 2016

Noitice - Meldonium / World Anti-Doping Agency (WADA). - 2016

A. Inclusion on the Prohibited List and excretions studies
B. Results management and adjudication
1. Results management shall proceed
2. Results management may be stayed
3. Cases where the concentration is below 1 μg/ml and the test was taken before 1 March 2016

iNADO Update (2016) 70 (25 April)
Institute of National Anti-Doping Organisations (iNADO)

Review of many (but by no means all) of the documents issued by WADA for the upcoming ExCo and Foundation Board meetings in Montreal on May 11 – 12, 2016.

- DG’s Report (Agenda Item 3.0)
- Independent Commission Report (Agenda Item 3.1)
- Single Testing Authority (“Olympic Summit Proposal”) (Agenda Item 3.2)
- 2019 World Anti- Doping Conference (Agenda Item 4.1)
- Athlete Committee Report (Agenda Item 5.1)
- 2016 Draft Financial Audit Report (Agenda Item 6.2)
- 2017 Budget – Preliminary Planning (Agenda Item 6.4)
- Science Department Report (Agenda Item 8.2)
- Blood Analytical Requirements (Agenda 8.3.2, including Attachments 1 and 2)
- Athlete Biological Passport (Agenda Item 9)
- Code Compliance (Agenda Items 10.1, 10.2 and 10.3)
- Mandatory Entry of Doping Control Forms and TUEs into ADAMS (Agenda Item 10.4)
- Modifications to the International Standard for Testing and Investigations (ISTI) (Agenda item 10.5 and Attachment 1)
- Legal and Investigations (Agenda Item 11.1 and Attachment 1)
- Whistleblower Policy (Agenda Item 11.2)
- NADO / RADO Relations (Agenda Item 15)
- Communications Report (Agenda Item 17)
- Standards and Harmonisation (Agenda Item 18)

Update on the status of Russia testing / WADA Executive Committee and Foundation Board. - World Anti-Doping Agency (WADA), 2016

- This report is intended to give an update from information provided on the status of the interim testing in Russia to the World Anti-Doping Agency (WADA) Executive Committee and Foundation Board on 11-12 May 2016.
- The report on 11-12 May was also posted on the WADA Web site
- The information provided in this report was collated in partnership with United Kingdom Anti-Doping (UKAD)
- The information contained in this report has also been shared with the International Association of Athletics Federations (IAAF) Anti-Doping Task Force

Status of Russia Testing / WADA Executive Committee and Foundation Board. - World Anti-Doping Agency (WADA), 2016

French version

Rapport d’étape sur les contrôles en Russie / Comité exécutif et du Conseil de fondation de l’AMA. - Agence mondiale antidopage (AMA), 2016

Status of Russia Testing / WADA Executive Committee and Foundation Board. - World Anti-Doping Agency (WADA), 2016

English version

Related case:
CAS 2016/A/4643 Maria Sharapova vs ITF
September 30, 2016

In March 2016 the International Tennis Federation (ITF) has reported an anti-doping rule violation against the Athlete Maria Sharapova after her samples, provided on 26 January and 2 February 2016 tested positive for the prohibited substance Meldronate (Meldonium). This substance is added on the WADA Prohibited List from 1 January 2016.
After notification the Athlete gave a prompt admission for the use of the substance, filed a statement with medical evidence in her defence and was heard for the ITF Independent Tribunal.

The Athlete stated she used the substance as medication since 2006 prescribed by Dr. Anatoly Skalny as treatment for her cold-related and inflammatory diseases. She admited that she does bear some fault because she did not know that the substance was prohibited since 1 january 2016. The use of the Mildronate was not known to any of the Athlete’s team members, the Athlete did not consult the WTA wallet card with prohibited substances and failed to mention the Meldronate on any Doping Control Form between 2014 en 2016.

The Tribunal concludes that the violation of the anti-doping rules was not intentional as the Athlete did not appreciate that Mildronate contained a substance prohibited from 1 January 2016. However she does bear sole responsibility for the violation, and very significant fault, in failing to take any steps to check whether the continued use of this medicine was permissible. If she had not concealed her use of Mildronate from the anti-doping authorities, members of her own support team and the doctors whom she consulted, but had sought advice, then the violation would have been avoided. She is the sole author of her own misfortune.

Therefore the Tribunal decides on 6 June 2016 to impose a 2 year period of ineliglibility on the Athlete Maria Sharapova starting on the date of the sample collection, i.e. on 26 January 2016.